Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Br J Haematol. 2016 Dec 19;176(5):759–769. doi: 10.1111/bjh.14480

Figure 3. Two-year overall survival.

Figure 3

HCVAD/MTX/Ara-C = HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate); R = rituximab.